Nuvo Research Inc.

Hznp Limited

Fqubed Inc.

Teikoku Pharma Usa, Inc.

Tioga Research, Inc.

Nuvo Pharmaceuticals Inc.

Exxon Research and Engineering Company

Hte Aktiengesellschaft the High Throughput Experimentation Company

Crescita Therapeutics Inc.

Dermala, Inc.

Permeatus, Inc.

Atossa Therapeutics, Inc.

John Michael Newsam

Jagat Singh

Bradley S Galer

Dominic King-Smith

Robert Dominic King-Smith

Joseph Zev Shainhouse

Lisa Marie Grierson

Samir M Mitragotri

Karl Gottlieb Strohmaier

Steven C Quay

Edward Thomas Kisak

Jonathan Wilkin

Maria Burian

Nadir Buyuktimkin

Servet Buyuktimkin

Ilya Feygin

Pankaj Sakharam Karande

Amit K Jain

Jianye Wen

Jutaro Shudo

Wade Hull

David E Vaughan

Stephan Andreas Schunk

Dirk Demuth

Wolfgang Strehlau

Armin Brenner

Jens Klein

Lada Rasochova

Wolfram Stichert

Ngoc Truc-Chi Vo

Tejas Desai

Edward T Kisak

Pankaj Karande

Michael M Treacy

R Dominic King-Smith

Avadhesh S Kushwaha

Amit Jain

The present disclosure relates generally to compositions of nitroglycerin and related organic nitrates, and methods for treating conditions such as Raynaud's phenomenon in which peripheral blood flow in a subject is compromised.

Topical formulations of nitroglycerin

Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid, Brij&#xae;-30 and a molecular penetration enhancer in a pharmaceutically acceptable preparation. The molecular penetration enhancer may include one or more of DMSO, dimethyl isosorbide, lauryl lactate and isopropyl myristate.

Compositions and methods for treating acne vulgaris

Provided herein are topical formulations. The topical formulation may comprise: (i) pregabalin, (ii) water, (iii) DMSO, (iv) a keto acid, and (v) and/or a fatty alcohol. The topical formulation may also comprise (i) pregabalin, (ii) DMSO, (iii) a keto acid and (iv) a fatty acid ester. It has been discovered that the combinations of DMSO with a keto acid such as levulinic acid and/or and a fatty acid ester such as lauryl lactate, or combinations of DMSO with a keto acid such as levulinic acid and/or with a fatty alcohol such as oleyl alcohol are excellent penetration enhancers and, as such, can be incorporated in a skin-applied formulation to facilitate administration of pregabalin.

Topical formulation

The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen.

Foamable formulation

The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.

Treatment of pain with topical diclofenac

The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes at least one corticosteroid, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.

Topical formulations for treating skin conditions

The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility.

Compositions and methods for transdermal delivery of hormones and other medicinal agents

The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a local anesthetic, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.

Topical formulations, systems and methods

Growing community of inventors

San Diego, CA, United States of America

John Michael Newsam